New Oral Treatments Are Reshaping Chronic Skin Care, Dermatologists Say
A new era in dermatology is underway. At the American Society for Dermatologic Surgery (ASDS) annual meeting and the inaugural DermNexus 2026 Congress, held in Scottsdale, Arizona, on November 20–21, 2026, specialists discussed how new oral medications are reshaping treatment for millions of people living with chronic skin conditions, including eczema, psoriasis, chronic hives, and hidradenitis suppurativa.
Central to the discussion were JAK inhibitors—pills and creams that block immune signals driving skin inflammation. These targeted therapies have expanded options for patients who previously had limited alternatives, offering the potential for clearer skin with fewer injections.
“When I was in training, there was such little available for people with chronic conditions, and then biologics kind of exploded,” said a dermatologist on the ASDS panel, noting that JAK inhibitors have since become “a solution for a lot of conditions that we didn’t have much before.”
At DermNexus, faculty highlighted nonsteroidal topical treatments, including ruxolitinib, delgocitinib, roflumilast, and tapinarof. Tapinarof, an aryl hydrocarbon receptor agonist, modulates inflammatory signaling while supporting skin-barrier repair.
The meeting also explored shared immune pathways in seemingly different conditions, such as vitiligo and alopecia areata, pointing toward more unified treatment strategies.
The FDA recently approved brepocitinib for dermatomyositis and pritelivir tablets for drug-resistant herpes simplex virus in immunocompromised patients, further expanding pill-based treatment options in dermatology.